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Reported recently in Lancet, Macchiarini and colleagues (2008) implanted a living tissue-engineered airway in
a female patient. The restoration of the patient’s quality of life testifies to this successful translation of bench-
top to bedside studies and provides promise for the application of regenerative medicine strategies to other
clinical disorders.PaoloMacchiarini and coworkers recently
used an engineered graft to replace
adiseasedportion ofwindpipe in awoman
who had failed all previous treatments,
and they succeeded in restoring
breathing function to this patient (Mac-
chiarini et al., 2008). Their strategy
involved use of a biologic scaffold in the
form of a donated human trachea that
was pretreated to remove endogenous
cells and immune-stimulatory proteins.
This scaffold was seeded with two popu-
lations of patient-derived cells: cultured
epithelial cells isolated by a small airway
biopsy, and cartilage cells derived
in vitro from bone marrow stem cells
(BMSCs) obtained from a needle aspirate.
The cell-seeded scaffold was placed
in a custom bioreactor and subjected
to hydrodynamic stimuli (similar to
breathing) and enhanced nutrition such
that the patient-derived cells integrated
with the donated tracheal scaffold and
produced living tissue. The surgery, in
which a 5 cm section of the left bronchus
was replaced with the tissue-engineered
graft, has restored normal lung function
in the patient. Further, follow-up biopsies
indicate revascularization and incorpora-
tion of the graft with no evidence of rejec-
tion at 4 months after surgery. Based on
this short-term success and their preclin-
ical animal studies (Jungebluth et al.,
2009; cited in Macchiarini et al., 2008),
the scientists and surgeons involved
remain cautiously optimistic regarding
the long-term outcome for this patient,
and enthusiastic about the potential impli-
cations of their work on the field of regen-
erative medicine. The authors are
thoughtful in their presentation, providing
context for their findings and demon-
strating a methodical approach fromlaboratory to patient. More importantly,
this study highlights the successful coor-
dination of areas under intensive research
in regenerative medicine, including inves-
tigation of cell sources, growth factors,
scaffolds, and bioreactors (Figure 1).
It is unlikely that a single tissue-engi-
neering blueprint can be developed that
would successfully repair and replace all
candidate tissues or organs, as the
optimal approach will need to be tailored
to the specific clinical demand, degree of
injury, tissue complexity, and required
function of the graft in each case, and will
likely also reflect the timely availability of
scaffolds and an appropriate cell source.
The feature that distinguishes the currentCell Stem Cadvance from previously reported
human-implanted engineered tissues
comprised of cellularized scaffolds (e.g.,
skin [Parenteau, 1999], cartilage [Ochi
et al., 2004], and bladder [Atala et al.,
2006]) is the incorporation of autologous
native differentiated cells and laboratory-
differentiated stem cells into a decellular-
ized human-donor scaffold. Encouraging
for the current trachea study, autologous
endothelial cell progenitor cell-seeded
human donor decellularized pulmonary
valves have been reported to remain func-
tional in two pediatric patients at 3.5 years
follow-up (Cebotari et al., 2006). The
overall impact of a strategy using alloge-
neic decellularized tissue scaffolds mayBasic
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Figure 1. Venn Diagram Depicting Tissue Engineering at the Intersection of Basic Science
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clinical problem to be addressed. The reli-
ance on human donor tissues predisposes
this approach to issues of insufficient
supply of healthy tissue of appropriate
size, concerns of disease transmission,
and regulations associated with tissue
retrieval, banking, matching, and distribu-
tion. While the detergent protocol used
for this work provides significant advan-
tage with respect to tissue processing
and matching, and the time frame for cell
seeding was very clinically relevant, the
hurdles of tissue availability, sizing,
banking, and distribution, as well as the
bioreactor treatment of the scaffolds, will
still need to be addressed before
widespread use of this type of tissue-
engineering strategy can be considered.
In order to develop an engineered struc-
ture to restore a functional airway in the
patient, the major requirements were to
establish a nonimmunogenic graft that
also exhibited functional mechanical
properties. The decellularized, detergent-
treated donor trachea fulfilled these
criteria. It was a tubular scaffold that
possessed the biochemical and structural
properties of healthy trachea tissue,
including hyaline cartilage rings to impart
mechanical strength and flexibility. Use
of a functional organ-donor scaffold can
greatly reduce the coculture time required
to seed cells prior to implantation, which
was 4 days in this case. In contrast,
tissue-engineering strategies using natural
or synthetic material-derived scaffolds to
grow tissues de novo typically require
weeks to months to achieve acceptable
levels of cell-elaborated tissue formation
and function prior to implantation.
Engineering of tissues (particularly
those that are in higher demand or require
more complex structures) may be more
readily pursued with a de novo tissue
fabrication approach, in that ‘‘from
scratch’’ engineering provides greater
flexibility in design and construct dimen-
sions, and no requirement for donor
tissue. In this context, bioreactors that
adopt a functional tissue-engineering
paradigm of physiologic loading (Butler
et al., 2000) have been used successfully
to create functional tissue in culture.
Deformational loading bioreactors, as an
example, concomitantly present a phys-
ical stimuli and enhanced nutrient and
growth factor transport to grow cartilage6 Cell Stem Cell 4, January 9, 2009 ª2009 Ewith native mechanical properties in vitro
(Mauck et al., 2003). An alternative to
these ex vivo approaches is the use of
the in vivo environment as the incubator
for tissue development. Biocompatible
scaffolds can be created with tissue-
specific functional mechanical properties
such that they can be immediately im-
planted (with or without cells) into patients
without preculture (Moutos et al., 2007). In
this strategy, the burden on the scaffold
and cells includes restoration of tissue
biochemical composition and structure
in addition to maintenance of functional
mechanical properties of the graft.
Optimal indications for ex vivo versus
in vivo strategies may vary based on
a number of patient-, technique-, and
application-related factors.
The turnaround time between initial cell
procurement and subsequent clinical
implantation of the engineered tissue is
also affected by the expediency of culture
protocols aimed at cell expansion and
commitment to or maintenance of a
desired differentiated phenotype prior
to scaffold seeding. A combination of
native differentiated epithelial cells and
BMSC-derived chondrocytes was used
in the current application, and other
groups have used, or hope to use, stem
cells from adipose tissue, muscle, embry-
onic stem cells, and induced pluripotent
stem cells (Takahashi et al., 2007) for
tissue engineering in regenerative medi-
cine. While the use of combinations of
cell types may offer advantages with
respect to regeneration of complex
tissues and organs, use of a single, readily
expandable cell source to generate
a range of tissues or organs is also attrac-
tive on many levels. The most efficacious
cell type in a given situation may depend
on the strategy being pursued and the
demands on the derived cells once
implanted.
While researchers have been success-
ful in guiding stem cells to express appro-
priate genes of a target differentiated cell
type using various stimuli, the ability of
stem cells to produce de novo tissue in
the laboratory thus far appears modest
at best. Therefore, the strategy of early
implantation with mechanically functional
scaffolds may be preferred for stem cell-
based strategies. As preclinical animal
studies from Macchiarini and coworkers
(Jungebluth et al., 2009) indicate thatlsevier Inc.growth factors from the decellularized
trachea may promote angiogenesis and
that cells from adjacent tissues can
rapidly repopulate the graft, it is possible
that preseeding of clinical grafts may be
unnecessary. Whichever the case may
be, strategies to optimize cell seeding
and attachment, recruitment, differentia-
tion, and synthetic activity via growth
factors or gene therapy enhancement of
scaffolds in conjunction with spatially
varying scaffold designs hold tremendous
promise for regenerative medicine.
The investigative team should be ap-
plauded for their significant achievement.
In their own words, ‘‘the findings suggest
that autologous cells combined with
appropriate biomaterials might provide
successful treatment for patients with
serious clinical disorders’’ (Macchiarini
et al., 2008). The encouraging results in
restoration of quality of life of the patient
serve as tangible motivation for the
maturing field of regenerative medicine
and reaffirm that fundamental basic
science studies can be successfully
translated to the clinic.
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